Add Yahoo as a preferred source to see more of our stories on Google. Dr Dao Nguyen examines a vial of lutein formulation developed for potential use in eyedrop treatments. (CREDIT: Will Wright, RMIT ...

Clearside Biomedical, Inc. has announced that its suprachoroidal injection delivery platform will be prominently featured at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las ...

An intravitreal ranibizumab injection was able to improve retinal sensitivity and thickness along with improving visual acuity. Branch retinal vein occlusion (BRVO) can affect people aged 40 years and ...

The FDA’s decision to extend the labeled duration of faricimab use in RVO beyond 6 months primarily reflects accumulated evidence supporting its continued efficacy and safety over longer treatment ...

When preparing for cataract surgery in patients with retinal pathologies, ophthalmologists must be sure to set reasonable ...

Intravitreal conbercept (IVC) loading injections alone leads to significant improvements in the microvasculature in proliferative DR.

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...

Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision impairment in adults, affecting ...

Dry age-related macular degeneration is the most common form of the disease, affecting millions of older Americans, according to the National Eye Institute. The condition develops ...

CHICAGO — The number of injections required for the successful treatment of neovascular age-related macular degeneration could be reduced considerably with experimental therapies, new research shows.

Retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy affect millions of people globally, often leading to vision loss with minimal straightforward treatment.